A Phase 1, Open-Label Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of PF-00734200 Administered To Subjects With Various Degrees Of Renal Impairment And Normal Renal Function.
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Gosogliptin (Primary)
- Indications Renal impairment
- Focus Pharmacokinetics
- Sponsors Pfizer
- 10 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Oct 2008 New trial record.